摘要
(ENPP2)也被称为自体毒素,是一种分泌溶血磷脂酶D,其水解溶血磷脂酰胆碱(LPC)成溶血磷脂酸(LPA)。LPA是ENPP2酶通过6 LPA-G-蛋白偶联受体(GPCR)诱导多种信号传导途径的生物活性产物。ENPP2为正常发展的重要蛋白质和其改变的表达与多种人类疾病有关。细胞的ENPP2沉默导致杀伤力在小鼠胚胎阶段。最初,它被鉴定为黑色素瘤细胞的自分泌因子。不同的研究小组目前正在探索理解ENPP2的各种处理,例如胚胎和神经发育,迁移,侵入,分化,增殖,血管生成和存活的多方面的作用。ENPP2的改变的表达也与各种疾病,如炎症,肿瘤,纤维化,类风湿性关节炎和神经缺陷有关。在本文中,我们总结ENPP2的结构方面,并与各种人类疾病,包括癌症和阿尔茨海默氏病(AD)的不同的细胞角色相关联的生化功能。此外,同时考虑与主张的调查结果,在各种植物化学物质和合成的抑制剂也提出目前探索作为靶向ENPP2函数关于各种人类疾病的治疗中的治疗剂的注释。
关键词: 核苷酸焦磷酸酯酶2,细胞增生,溶血磷脂酸,磷脂酶D
Current Molecular Medicine
Title:Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases
Volume: 15 Issue: 10
Author(s): R. P. Cholia, H. Nayyar, R. Kumar and A. K. Mantha
Affiliation:
关键词: 核苷酸焦磷酸酯酶2,细胞增生,溶血磷脂酸,磷脂酶D
摘要: Ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2) also known as Autotaxin, is a secreted lysophospholipase D, which hydrolyzes lysophosphatidylcholine (LPC) into Lysophosphatidic acid (LPA). LPA is the bioactive product of ENPP2 enzyme, which induces diverse signalling pathways via six LPA-G-protein coupled receptors (GPCRs). ENPP2 is an essential protein for normal development and its altered expression is associated with various human diseases. Cellular ENPP2 silencing results in lethality at the embryonic stage in mice. Initially, it is identified as an autocrine factor in melanoma cells. Different research groups are currently exploring to understand the multifaceted role of ENPP2 in various processes such as embryonic and neural development, migration, invasion, differentiation, proliferation, angiogenesis, and survival. Altered expression of ENPP2 is also associated with various diseases like inflammation, cancer, fibrosis, rheumatoid arthritis and neural defects. In this article, we have summarized structural aspects of ENPP2 and biochemical functions associated with its diverse cellular roles in various human diseases including cancer and Alzheimer’s disease (AD). In addition, keeping in view and advocating findings, a note on various phytochemicals and synthetic inhibitors, which are currently explored as therapeutic agents targeting functions of ENPP2 for the treatment of various human diseases is also presented.
Export Options
About this article
Cite this article as:
R. P. Cholia, H. Nayyar, R. Kumar and A. K. Mantha , Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases, Current Molecular Medicine 2015; 15 (10) . https://dx.doi.org/10.2174/1566524015666150921104804
DOI https://dx.doi.org/10.2174/1566524015666150921104804 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets Bicycloheptylamine-Doxorubicin Conjugate: Synthesis and Anticancer Activities in σ2 Receptor-Expressing Cell Lines
Medicinal Chemistry MET and ALK as Targets for the Treatment of NSCLC
Current Pharmaceutical Design The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine Deglucohellebrin: A Potent Agent for Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry PET Imaging for Gene & Cell Therapy
Current Gene Therapy The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes
Current Pharmaceutical Design Progress on Multi-Modality Molecular Imaging
Current Medical Imaging Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets Diazenyl Derivatives as Therapeutic and Diagnostic Agents Acting on Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Retracted: miR-27b-3p Inhibits Invasion, Migration and Epithelial-mesenchymal Transition in Gastric Cancer by Targeting RUNX1 and Activation of the Hippo Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Major Developments in the Design of Inhibitors along the Kynurenine Pathway
Current Medicinal Chemistry Blockade of Furin Activity and Furin-Induced Tumor Cells Malignant Phenotypes By The Chemically Synthesized Human Furin Prodomain
Current Medicinal Chemistry Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry New Therapeutic Strategies for Cancer and Neurodegeneration Emerging from Yeast Cell-based Systems
Current Pharmaceutical Design Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes
Current Radiopharmaceuticals Nucleic Acids as Therapeutic Agents
Current Topics in Medicinal Chemistry Human Cytomegalovirus US28: A Functionally Selective Chemokine Binding Receptor
Infectious Disorders - Drug Targets